Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma

This study has been completed.

Study NCT00075400 Information provided by National Cancer Institute (NCI)

First Received: January 9, 2004 Last Updated: August 17, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Publications:

Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec(R)) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010 Feb 25; [Epub ahead of print]

Back to top of Main Content